ДИССЕМИНИРОВАННЫЙ НЕМЕЛКОКЛЕТОЧНЫЙ РАК ЛЕГКОГО: ВОЗМОЖНОСТИ ЛЕКАРСТВЕННОЙ ТЕРАПИИ В ПЕРВОЙ ДЕКАДЕ XXI ВЕКА

В обзоре представлены данные о распространенности рака легкого (РЛ) в РФ и мире. Обсуждается эффективность различных скрининговых методик, применяемых для выявления больных РЛ, ценность различных диагностических методов. Представлены данные о современной лекарственной терапии немелкоклеточного РЛ, построенной на основе дуплетов цисплатина и карбоплатина, используемых в 1-й линии терапии, а также дуплетов, не содержащих цисплатин или карбоплатин, обычно применяемых во 2-й линии терапии, и таргетных препаратов, назначаемых раздельно или в комбинации с химиотерапией. Указана эффективность отдельных режимов химиотерапии, приведены данные об одно-, иногда двухгодичной выживаемости, медианы выживаемости, основные проявления токсичности комбинаций, дозы лекарств и подробные схемы их назначения.

1. Haddadin S., Perry M.C. History of small-cell lung cancer. Clin Lung Cancer 2011;12:2;87–93.

2. Rosenblatt M.B. Lung cancer in the 19th century. Bull Hist Med 1964;38:395–25.

3. Morriston Davies H. Recent advances in the surgery of the lung and pleura. Br J Surg 1913;1(2):228–58.

4. Horn L., Johnson D.H., Evarts A. Graham and the first pneumonectomy for lung cancer. J Clin Oncol 2008;26:3268–75.

5. Doll R., Hill A.B. Smoking and carcinoma of the lung preliminary report. BMJ 1950;2:739–48.

6. Parkin D.M., Bray F., Ferlay J., Pisani P. Global Cancer Statistics, 2002. CA 2003;55:74–108.

7. Аксель Е.М., Давыдов М.И. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2008 году. Вестник РОНЦ им. Н.Н. Блохина РАМН 2010;21(2):52–86.

8. Berlin N.I., Buncher C.R., Fontana R.S. et al. The National Cancer Institute Cooperative Early Lung Cancer Detection Program: results of the initial screen (prevalence): early lung cancer detection:

9. introduction. Am Rev Respir Dis 1984;130:545–9.

10. Fontana R.S., Sanderson D.R., Woolner L.B. et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991;67(4 Suppl):1155–64.

11. Melamed M.R., Flehinger B.J., Zaman M.B. et al. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 1984;86(1):44–53.

12. Eguchi K., Henschke C. Meeting Summary of the 12th International Conference on Screening for Lung Cancer: Nara, Japan, April 2005. J Thorac Oncol 2006;1:190–7.

13. Karnofsky D.A., Craven L.F., Burchenal J.A. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634–51.

14. Lung Cancer. Dana-Farber Cancer Institute. A. Skarin, P. Lorigan, eds. Elsevier, 2007.

15. Bonomi P., Kim K., Fairclough D., et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin

16. Oncol 2000;18(3):623–31.

17. Rossel R., Gatzemeier U., Betticher D.C., et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002;13(10):1539–49.

18. Shiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92–8.

19. Fossela F., Pereira J.R., von Pawel J., et al. Randomized multinational phase III study of docetaxel +

20. platinum combinations versus vinorelbin plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21(16):3016–27.

21. Sandler A.B., Nemunaitis J., Denham C., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Ann

22. Oncol 2000;18:122–30.

23. Wozniak A.J., Crowley J.J., Balcerzak S.P., et al. Randomized trial comparing cisplatin + cisplatin plus vinorelbin in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16(17):2459.

24. Nagao K.A., Fukuoka M, Fujita A, et al. A phase II study of irinotecan combined with cisplatin in non-small cell lung cancer. CPT-11 Lung Cancer Study Group. Gan To Kagaku Ryoho 2000;27(3):413–21.

25. Kelly K., Granley J., Bunn P.A. Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbin plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19(13):3210–8.

26. Pallis A.G., Syrigos K., Kotsakis A. et al. Second-line paclitaxel/carboplatin versus vinorelbin/carboplatin in the patients who have advanced non-small-cell lung cancer pretreated with non-platinum based chemotherapy: a multicenter randomized phase II study. Clin Lung Cancer

27. ;12(2):100–9.

28. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29(1 Suppl4):27–36.

29. Sederholm C., Hillerdal G., Lamberg K., et al. Phase III trial of gemcitabine plus carboplatin versus gemcitabine alone in metastatic NSCLC: the Swedish lung cancer croup. J Clin Oncol 2005;23:8380–8.

30. Cancer – matrix manual. 5th edition – a multidisciplinary. E.H. Lin, R. Losano, eds. Advanced Medical Pub Inc, 2010.

31. Kosmas C., Tsavaris N., Vadiaka M., et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with non-small-cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001;92(11):2902–10.

32. Muñoz A., Rubio I., Mañé J.M., et al. Phase II study of docetaxel/vinorelbine in patients with non-small-cell-lung cancer previously treated with platinumbased chemotherapy. Clin Lung Cancer

33. ;4(3):168–73.

34. Azzoli C.G., Baker S. Jr., Temin S., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27(36):6251–66.

35. Beretta G. Mitomycin C.: fifty years’ medical experience. Turin: Edizioni Minerva Medica, 2004.

36. Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И. Переводчикова. М.: Практическая медицина, 2011.

37. Katakani N., Nishimura T., Sigiura T. et al. Vinorelbin plus gemcitabine in the treatment of chemotherapy naive stage IIIB/IV non-small-cell lung cancer. Available from: http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst_detail_view&confID=10&abstractID=2773

38. Dassonville O., Bozec A., Fischel J.L., Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinas inhibitors. Similarities and differences. Grit Rev Oncol Hemat 2007;62(1):53–61.

39. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

40. J Clin Oncol 2003;21(12):2237–46.

41. Perer-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238–47.

42. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet

43. ;366(9496):1527–37.

44. Stewart D.J. Targeted therapy in nonsmall cell lung cancer. In: Targeted Cancer Therapy. Kurzrock R. and Markman M. eds. Humana Press, 2008.

45. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542–50. Eur Heart J 2009;30(19):2369–413.